Browse by Medical Category
Support the Cellular Immunotherapy Program
The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells.
The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells. Our approach is to expand cellular engineering and immunotherapy research by bringing together physicians and laboratory scientists focused on immune cell engineering and its clinical effects. We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies, with the ultimate goal of developing curative treatments for cancer and other diseases.
Kiss 108 FM’s Billy Costa talks with four experts from the Mass General Cancer Center to learn about what CAR T-Cell Therapy is and what impact it has on both patients and the medical community. More Videos
Leadership Maus Laboratory Clinical Investigators Immune Monitoring Laboratory Blood Transfusion Service Cellular Therapy and Transplantation Laboratory
The Cellular Immunotherapy Program is lead by Marcela Maus, MD, PhD.
Director, Cellular Immunotherapy Program, Massachusetts General HospitalAssistant Professor of Medicine, Harvard Medical School
Marcela Maus, MD, PhD, is Director of the Cellular Immunotherapy Program and a member of the Center for Cancer Immunology at Mass General. Her work aims to understand and engineer novel forms of cellular therapies – using cells normally produced by our bodies – to treat patients with cancer. Cellular therapies have achieved unprecedented, durable responses in some blood cancers, particularly CAR-T cell therapy in acute lymphoblastic leukemia. These results demonstrate the tremendous power of engineering the immune system to recognize and eliminate tumor cells, and effect long-term clinical benefit. However, to be able to harness this power of the cellular immune system in other cancers, there is a need to identify and validate new targets, and to develop ways of enhancing both the safety and effectiveness of imperfect targets. Dr. Maus is building the Cellular Immunotherapy Program to create new and improved treatments for patients with leukemia, myeloma and brain tumors initially, but hopes to expand the program over time to cover numerous tumor types.
The goal of the Maus lab is to design and evaluate next generation genetically-modified (CAR) T cells as immunotherapy in patients with cancer. Learn more.
To bring therapies to patients, a dedicated team of early-phase clinical investigators in oncology play a central role in cancer immunology at Mass General.
Director, Jon and JoAnn Hagler Center for Lymphoma Massachusetts General Hospital
Director, BMT ProgramMassachusetts General Hospital
Director, Center for LeukemiaMassachusetts General Hospital
Center for Thoracic CancersMassachusetts General Hospital
Director, Hematologic Malignancy ProgramMassachusetts General Hospital
Director, Cellular Immunotherapy ProgramMassachusetts General Hospital
Director, Center for Multiple MyelomaMassachusetts General Hospital
Center for Multiple MyelomaMassachusetts General Hospital
The Immune Monitoring Laboratory is an essential and integral part of the Cellular Immunotherapy Program. The laboratory provides expertise to enable translational clinical studies of immune-based therapies, based on the highest standard operating systems. Learn more.
The Blood Transfusion Service is an FDA-licensed, full-service blood bank that consists of the Blood Donor Center, the Outpatient Infusion Unit, the Apheresis Unit, the Transfusion Service, and the Histocompatibility (HLA) Laboratory. Learn more.
Associate Director, Blood Transfusion ServiceMassachusetts General Hospital
The Mass General Cancer Center’s Cellular Therapeutics and Transplantation Laboratory (CTTL) is comprised of a team of medical technologists that provide support to the Bone Marrow Transplant Program. These technologists play an integral part in stem cell processing, transplant infusions and bone marrow harvests. Technologists also participate in numerous immunotherapy clinical trials to aid in the progression of research and improve patients’ lives. Learn more.
CTTL Medical DirectorMassachusetts General Hospital
View Cellular Therapy clinical trials.
CAR T-cell Therapy for Lymphoma: Yescarta
The Mass General Cancer Center is an authorized treatment center for Yescarta (axicabtagene ciloleucel), FDA approved CAR T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Learn more here.
Learn more about CAR T-Cell Therapy in this series of videos. Kiss 108 FM’s Billy Costa talks with four experts from the Mass General Cancer Center to learn about what CAR T-Cell Therapy is and what impact it has on both patients and the medical community.
Watch how Mass General patient Jenn Gilmann has already benefited from immunotherapy.
A new immunotherapy program at the Mass General Cancer Center is using engineered cells from the human immune system as powerful living drugs.
The Center for Cancer Immunology’s investigators are working to expand the use of immunotherapy, a revolutionary approach to cancer therapy.
View publications by Marcela Maus, MD, PhD on PubMed.
Cellular Immunotherapy Expert Explains CAR T-Cell Therapy Excitement
CAR-T engineering of patients’ own T cells for cancer therapy gains traction
For Some, Cutting-Edge 'CAR-T' Treatment Unleashes 'Pac-Man' Cells Against Blood Cancer
Guest commentary: Early trials support use of CAR T-cell therapy in glioblastoma
CRISPR Therapeutics Joins Hospital For Cancer Treatment Tests
Stand Up To Cancer Awards Innovative Research Grants in Immuno-oncology to 10 Early-career Scientists
The Mass General Cancer Center is an authorized treatment center for Yescarta, FDA approved CAR T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Learn more here.
Cellular Immunotherapy Program team members selected as 2017 MGH the one hundred honorees for their commitment to the fight against cancer.
As the director of the Cellular Immunotherapy Program at the Mass General Cancer Center, Marcela Maus, MD, PhD, is following a childhood dream of fixing genes gone wrong in the pursuit of a cure for cancer.
Using the immune system as a cancer treatment has the potential to induce long-term, durable remissions, and perhaps even cures for some patients. Dr. Maus realizes the incredible potential of this kind of treatment. She’s working to create new and improved immunotherapy treatments for patients with leukemia, multiple myeloma and brain tumors initially, but hopes to expand the program over time to cover numerous tumor types. “Over the years, I’ve become a specialist in T cells, which have three amazing and important properties. They can kill other cells they see as a target; they can be turned on and off by specific signals; and they stick around for your whole life. I want to get to know T cells very well, how they work, and how we can get them on our side,” Dr. Maus explains. “Enlisting and directing T cells has the potential to cure cancer, which is a crazy ambitious goal, but that is my dream.”
Contact the Mass General Hospital Cellular Immunotherapy ProgramEmail: MGHCIP@mgh.harvard.edu
Your support can help advance the research and development of promising cellular therapies that can harness the immune system to fight cancer.
Make a Gift Now
Back to Top